Psychopharmacology Bulletin

• 

  Publication Venue For

  • Effectiveness of a brain-computer interface based programme for the treatment of ADHD: a pilot study..  43:73-82. 2010
  • Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis..  42:11-31. 2009
  • Patterns of pharmacotherapy and treatment response in elderly adults with bipolar disorder..  41:102-114. 2008
  • Atypical antipsychotics and pituitary neoplasms in the WHO database..  40:74-76. 2007
  • Cognitive behavioral approaches to the treatment of pain..  40:74-88. 2007
  • Donepezil for cognitive decline following coronary artery bypass surgery: a pilot randomized controlled trial..  40:54-62. 2007
  • Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study..  40:47-56. 2007
  • Evidence-based treatment of psychiatric disorders with comorbid medical illnesses: the need for large simple clinical trials..  40:5-11. 2007
  • Predicting antipsychotic use in children..  40:116-124. 2007
  • A randomized controlled trial of paroxetine for noncardiac chest pain..  39:15-24. 2006
  • Suicide risk analysis among patients assigned to psychotropics and placebo..  39:6-14. 2006
  • Alzheimer's disease and the glutamate NMDA receptor..  37:41-49. 2003
  • An evidence-based medicine approach to combined treatment for ADHD in children and adolescents..  37:7-23. 2003
  • Cholesterol-lowering medication and relapse of depression..  37:92-98. 2003
  • Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination..  37:73-87. 2003
  • Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression..  37:67-78. 2003
  • Evidence for the treatment of borderline personality disorder..  37:30-46. 2003
  • Evidence-based decision-making in psychopharmacology..  37:24-28. 2003
  • Evidence-based mental health use of anticonvulsants during pregnancy..  37:59-66. 2003
  • Evidence-based practice: how to evaluate what you read..  37:88-91. 2003
  • Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: review and update..  37:120-134. 2003
  • Treatment of posttraumatic stress disorder: the impact of paroxetine..  37 Suppl 1:76-88. 2003
  • Antipsychotic medications and sudden cardiac death..  36:91-99. 2002
  • Evidence-based mental health..  36:27-34. 2002
  • Management of late-life depression: focus on comorbid conditions..  36:113-130. 2002
  • Practical evidence-based medicine..  36:20-26. 2002
  • The Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) approach..  36:58-68. 2002
  • Treatment of thyrotoxicosis-induced psychosis..  36:7-13. 2002
  • Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease..  35:83-96. 2001
  • Informant-rated cognitive symptoms in normal aging, mild cognitive impairment, and dementia. Initial development of an informant-rated screen (Brief Cognitive Scale) for mild cognitive impairment and dementia..  35:79-88. 2001
  • Evidence report on: Treatment of depression - Newer pharmacotherapies.  34:409-795. 1998
  • Pivotal studies of clonazepam in panic disorder..  34:169-174. 1998
  • Treatment of depression--newer pharmacotherapies..  34:409-795. 1998
  • Memory, language, and praxis in Alzheimer's disease: norms for outpatient clinical trial populations..  33:123-128. 1997
  • The Alzheimer's disease assessment scale .6. Noncognitive signs and symptoms in outpatients with Alzheimer's disease.  33:514-514. 1997
  • A curbstone consult to applicants for National Institute of Mental Health grant support..  32:311-320. 1996
  • Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)..  32:67-73. 1996
  • The Alzheimer's Disease Assessment Scale: Predictors of baseline cognitive performance in clinical trials.  32:434-434. 1996
  • From scientific knowledge to the clinical practice of psychopharmacology: can the gap be bridged?.  31:7-20. 1995
  • Treatment of chronic depression with sertraline or imipramine: preliminary blinded response rates and high rates of undertreatment in the community..  31:205-212. 1995
  • Treatment optimization with ECT..  30:313-320. 1994
  • Diagnosis and treatment of depression in late life: the NIH Consensus Development Conference Statement..  29:87-100. 1993
  • Efficacy of treatments for major depression..  29:457-475. 1993
  • Does sigma receptor antagonism predict clinical antipsychotic efficacy?.  27:103-106. 1991
  • Electroconvulsive therapy in the United States..  27:9-15. 1991
  • Predictors of therapeutic response to haloperidol in acute schizophrenia..  27:97-101. 1991
  • Meal-related cholecystokinin secretion in eating and affective disorders..  25:444-449. 1989
  • Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease..  24:641-652. 1988
  • Kraepelinian schizophrenia: a subgroup of schizophrenia?.  24:56-61. 1988
  • The effects of amantadine vs. trihexyphenidyl on memory in elderly normal volunteers.  23:30-32. 1987
  • Anticholinergic prophylaxis in young adults treated with neuroleptic drugs.  22:981-984. 1986
  • ELECTRICAL DOSAGE, STIMULUS PARAMETERS, AND ELECTRODE PLACEMENT.  22:499-502. 1986
  • Reliability and validity of SAFTEE: Preliminary analyses.  22:397-401. 1986
  • The inventory of depressive symptomatology (IDS): Preliminary findings.  22:985-990. 1986
  • The relationship between panic disorder and agoraphobia: an epidemiologic perspective..  22:787-791. 1986
  • A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression.  20:73-78. 1984
  • The first clinical study of BW-234U in schizophrenia..  18:173-176. 1982
  • The role of stimulus waveform in therapeutic and adverse effects of ECT..  18:71-72. 1982
  • Cerebral blood flow in depression and mania.  18:6-8. 1982
  • Efficacy of ECT in the treatment of depression: Wave form and electrode placement considerations.  18:31-34. 1982
  • Evaluation of the central nervous system risks of ECT.  18:29-31. 1982
  • Heterogeneity in the response pattern of organ systems to stress: Mediators and mechanisms.  18:96-99. 1982
  • Model utility in postpartum psychosis.  18:184-187. 1982
  • Biological and/or genetic factors in alcoholism..  17:37-42. 1981
  • Sleep EEG and dexamethasone suppression testing findings in unipolar depressions.  17:22-23. 1981
  • The sympathetic nervous system as a model for studying drug-induced alterations of nerve development.  17:151-153. 1981
  • Peripheral alpha-adrenergic receptor subtypes..  16:90-91. 1980
  • Drugs and psychotherapy in the treatment of depressions.  16:60-62. 1980
  • The efficacy of new pharmacological treatments for panic disorder: evaluating the trials. 1998
  • Algorithm for the treatment of panic disorder with agoraphobia. 1995
  • Plasma GABA in mood disorders. 1990
  • Posttraumatic stress disorder: Recent advances in basic science and clinical research 1989
  • Pharmacotherapy in posttraumatic stress disorder: historical and clinical considerations and future directions. 1989